News / Taiwan / economic_daily
Taiwan Accelerates Drug Approval Process, Biotech Stocks Surge
Health Technology · Biotechnology · economic_daily · 2026-09-23
4174, 6610, 6696, 6838, 7924
Taiwan's health ministry plans to cut new drug approval times to 100 days, sparking a rally in local biotech stocks like TLC-KY amid improved regulatory outlooks.
What Happened
Policy Shift: The Ministry of Health and Welfare aims to boost the domestic pharmaceutical industry by shortening new drug approval times to 100 days. By implementing parallel reviews with national health insurance coverage, the government intends to outpace the regulatory timelines seen in the US, EU, and Japan.
Market Rally: Biotech stocks responded positively to the news, with TLC-KY surging 70% over five days. Other industry players, including Anchen Biotech and TaiGen Biotechnology, also saw significant gains as investors cheered the improved regulatory environment.
TLC-KY Pipeline: TLC-KY is nearing a critical milestone for its non-opioid post-operative pain relief drug, TLC590. The company has completed patient follow-ups for its Phase III trial and is preparing for data analysis and unblinding, which could catalyze future global partnerships.
Growth Potential: With over 300 million surgeries performed globally each year, the demand for non-addictive, high-efficacy pain management is substantial. TLC590’s ability to provide 168 hours of pain relief with a superior safety profile positions it well for the massive US surgical market.